Description of Invention:
Inherited prostate cancer susceptibility genes with high penetrance are responsible for 5% to 10% of all cancer cases and up to 30% to 40% of early onset of the disease. Previous genetic linkage studies indicated that germline variations in a gene or genes on Xq27 were involved in prostate carcinogenesis. The linkage peak for prostate cancer overlies a region containing five SPANX genes whose expression has been detected in a variety of cancers. The investigators have identified an intra-chromosomal inversion involving more than a 400 kb sequence in prostate cancer patients but not in unaffected individuals. This technology can be used as an accurate, early prostate cancer susceptibility diagnostics method.
Applications:
High throughput screening assay to predict patient susceptibility to prostate cancer
Advantages:
Easy, ready to use early stage prostate cancer diagnostic
Development Status:
The technology is currently in the pre-clinical stage of development.
Market:
Among men, prostate cancer is the most common cancer and the second leading cause of death.
There will be approximately 186,320 newly diagnosed cases of prostate cancer and an estimated 28,660 deaths are expected to occur in the United States in 2008.
An estimated 5 to 10 percent of all prostate cancers are considered hereditary and as many as 30% to 40% of early onset of the disease.
Inventors:
Natalay Kouprina (NCI) et al.
Patent Status:
DHHS Reference No. E-241-2007/0 --
U.S. Provisional Application No. 61/010,209 filed 01 Jan 2008
Licensing Status: Available for exclusive or non-exclusive licensing.
Portfolios: Gene Based Therapies Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics Gene Based Therapies -Diagnostics
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
